Renalytix gets KidneyIntelX included in major clinical guidelines

21st Aug 2023 12:39

(Sharecast News) - Renalytix announced on Monday that its signature solution 'KidneyIntelX' has secured a spot in the draft Kidney Disease Improving Global Outcomes (KDIGO) 2023 clinical practice guideline for the evaluation and management of chronic kidney disease.

The AIM-traded firm said the KDIGO guidelines are considered authoritative in the world of kidney disease management, encompassing an exhaustive process that bridges comprehensive global scientific evidence reviews with actionable recommendations for medical practitioners and their patients.

With the close of the 30-day public comment period, which began in July, the final rendition of the KDIGO 2023 guideline was set for release in the final quarter of the year.

Renalytix said it was confident that KidneyIntelX's inclusion in the KDIGO 2023 guideline could potentially catalyse its broader adoption across medical circuits.

The company said it expected that the nod would bolster clinical acceptance, and pave the way for reimbursement prospects, particularly for testing that assesses the risk for patients with type-2 diabetes and early-stage kidney disease, not only in the US but on a global scale.

"KDIGO is a global non-profit organisation developing and implementing evidence-based clinical practice guidelines in kidney disease that are followed by clinicians in the United States and around the world," the Renalytix board said in its statement.

"It is an independent foundation incorporated in Belgium and accountable to the public and the patients it serves.

"KDIGO has a network of dedicated volunteers from around the world who promote awareness, dissemination, adoption, and clinical integration of KDIGO Guidelines both globally and in their respective countries or regions."

At 1027 BST, shares in Renalytix were up 2.55% at 99.99p.

Reporting by Josh White for Sharecast.com.